Development

INSIGHTS ON DRUG DEVELOPMENT

Multiplex Imaging
Explore recombinant antibody reagents that support the imaging of key targets within the TME and offer flexible solutions across various platforms to improve patient outcomes.
A Novel Patient-Derived Colorectal Cancer Organoid Platform
Patient-derived organoids are revolutionizing drug discovery by mimicking tumors and predicting therapeutic efficacy. Discover a scalable bioprocess that enhances reproducibility and cost-effectiveness to pave the way for broader adoption.
Advancing In Silico Predictions In Early Drug Discovery
Examine a high-throughput approach that streamlines LogD measurements, offering faster and more accurate insight into compound lipophilicity to support better decision-making in early drug discovery.
Topliss Sets In Drug Design Technical Notes For The Medicinal Chemist
When considering new, innovative, and efficient drug design processes, you may want to review Professor J G Topliss's non-mathematical operational schemes for analogue design.

Identify And Mitigate Absorption Risks With PBPK Modeling
3/12/2024

See how PBPK models combined with custom and off-the-shelf in vitro tools and solubility enhancement expertise can reduce the need for drug product reformulation or repeated preclinical or clinical studies.
Assessing E&Ls From Single-Use Systems Used In ATMP Production
11/21/2024

Explore the impact of extractables and leachables (E&Ls) in CGT development. Learn how to qualify single-use systems and use cell-painting assays to assess E&L effects.
Studying The Spatial Architecture Of Glioblastoma
3/24/2025

Explore how intra-tumor heterogeneity (ITH) impacts cancer progression and therapy resistance with advanced imaging platforms and custom antibody panels to reveal the spatial architecture of glioblastoma (GBM).
Increasing Bioavailability With Amorphous Solid Dosage Formulations
11/10/2023

Discover the challenges associated with pH-dependent solubility for oral tyrosine kinase inhibitor drugs and how leveraging ASD formulation can help create more effective, patient-friendly drug products.
Assessing Viability And Real-Time Apoptosis/Necrosis
3/17/2025

Malignant gliomas are aggressive brain tumors that resist standard treatments. Discover why researchers focus on real-time cell death dynamics to develop targeted therapies and promising strategies.

Trusted End-To-End CDMO Partner For Your Journey

In an increasingly competitive environment, working with the right CDMO is vital for successful drug lifecycle management. We now serve more than half of the world’s leading biopharmaceutical companies, sharing their mission to expedite patient access to life-saving biologics.
Early Development: Accelerating Molecules Through To Proof-Of-Concept

Our integrated approach brings together drug substance, drug product and clinical activities, supporting the expediting of lead molecules from FIH into POC trials.
A Quick Guide To Dissolution Testing

What is dissolution testing? Why is it critical? What should you consider for your method validation? Find answers to these questions and more in this quick guide to dissolution testing.
Transforming Tissue Research With Open Multiplexing

Cell DIVE Multiplex Imaging Solution

What if every scientist could map normal and diseased tissue by cell type, biomarker profile, and specific features?

Cell DIVE is a precise, open multiplexing solution that lets your research dictate the level of automation required, which antibodies to use, how to build your antibody panel, and more.
Integrated Programs To Bridge Molecules From Discovery Into Clinical Development

A new collaboration helps to remove obstacles from the critical path, reduce development risks, eliminate the white space in pre-clinical drug development, and shorten the pathway to clinical development.